DK2321351T3 - Antistoffer mod ccr2 - Google Patents
Antistoffer mod ccr2 Download PDFInfo
- Publication number
- DK2321351T3 DK2321351T3 DK09789161.8T DK09789161T DK2321351T3 DK 2321351 T3 DK2321351 T3 DK 2321351T3 DK 09789161 T DK09789161 T DK 09789161T DK 2321351 T3 DK2321351 T3 DK 2321351T3
- Authority
- DK
- Denmark
- Prior art keywords
- ccr2
- antibody
- seq
- amino acid
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
Claims (19)
1. Isoleret humant monoklonalt antistof eller antigenbindende del deraf, der binder specifikt til C-C-kemokin-receptor type 2 (CCR2), omfattende en tung-kæde-variabelt (VH) domæne-aminosyresekvens omfattende en VH-CDR1 som angivet i SEQ ID NO:84, en VH-CDR2 som angivet i SEQ ID NO:85 og en Vh-CDR3 som angivet i SEQ ID NO:86; og en letkæde-variabelt (VL) domæne-aminosyresekvens omfattende en VL-CDR1 som angivet i SEQ ID NO:102, en VL-CDR2 som angivet i SEQ ID NO:103 og en VL-CDR3 som angivet i SEQ ID NO:104.
2. Isoleret humant monoklonalt antistof eller antigenbindende del deraf ifølge krav 1, omfattende en tungkæde-variabelt (VH) domæne-aminosyresekvens udvalgt fra gruppen bestående af: SEQ ID NO:83 med en konservativ amino-syresubstitution, SEQ ID NO:83 med en kimbane-aminosyresubstitution sammenlignet med SEQ ID NO:160 og en aminosyresekvens, der er mindst 90 % identisk med SEQ ID NO:83, hvor CDR'erne er som defineret i krav 1.
3. Isoleret humant monoklonalt antistof eller antigenbindende del deraf ifølge krav 1, omfattende letkæde-variabelt (VL) domæne-aminosyresekvensen udvalgt fra gruppen bestående af: SEQ ID NO:101, SEQ ID NO:113, SEQ ID NO:101 med en konservativ aminosyresubstitution, SEQ ID NO:113 med en konservativ aminosyresubstitution, SEQ ID NO:101 med en kimbane-aminosyresubstitution sammenlignet med SEQ ID NO:161, SEQ ID NO:113 med en kimbane-aminosyresubstitution sammenlignet med SEQ ID NO: 161, en aminosyresekvens, der er mindst 90 % identisk med SEQ ID NO:101, og en aminosyresekvens, der er mindst 90% identisk med SEQ ID NO:113, hvor CDR'erne er som defineret i krav 1.
4. Isoleret humant monoklonalt antistof eller antigenbindende del deraf ifølge krav 1, omfattende tungkæde-variabelt (VH) domæne-aminosyresekvensen med SEQ ID NO:83 og letkæde-variabelt (VL) domæne-aminosyresekvensen med SEQ ID NO:113.
5. Isoleret humant monoklonalt antistof eller antigenbindende del, der binder specifikt til CCR2, omfattende: tungkæde-CDR1, -CDR2 og -CDR3 fra den tunge kæde af et monoklonalt antistof, der er produceret af hybridomet betegnet med ATCC-accessionsnr. PTA-6980; og letkæde-CDR1, -CDR2 og -CDR3 fra den lette kæde af det monoklonale antistof, der er produceret af hybridomet betegnet med ATCC accessionsnr. PTA-6980.
6. Isoleret humant monoklonalt antistof eller antigenbindende del ifølge krav 1, idet antistoffet har den tunge kæde og den lette kæde udvalgt fra gruppen bestående af: a) den tunge kæde med en aminosyresekvens med SEQ ID NO:82 og den lette kæde med en aminosyresekvens med SEQ ID N0:100; eller b) den tunge kæde med en aminosyresekvens med SEQ ID NO:116 og den lette kæde med en aminosyresekvens med SEQ ID NO:112.
7. Isoleret humant monoklonalt antistof eller antigenbindende del ifølge krav 1, hvor tungkæde-aminosyresekvensen er SEQ ID NO:116, og letkæde-aminosyresekvensen er SEQ ID NO:112.
8. Isoleret humant monoklonalt antistof eller antigenbindende del ifølge krav 1, yderligere omfattende en eller flere VH-FR1, -FR2, -FR3 eller -FR4 og/eller VL-FR1, -FR2, -FR3 eller -FR4-aminosyresekvens af en antistof-tung- eller let-kædesekvens udvalgt fra gruppen bestående af: SEQ ID NO:82, SEQ ID NO:100, SEQ ID NO:116 og SEQ ID NO:112.
9. Isoleret humant monoklonalt antistof eller antigenbindende del ifølge krav 8, yderligere omfattende et tungkæde-konstant domæne.
10. Isoleret humant monoklonalt antistof eller antigenbindende del ifølge krav 9, yderligere omfattende et letkæde-konstant domæne.
11. Farmaceutisk sammensætning omfattende det isolerede humane monoklonale antistof eller den antigenbindende del ifølge et hvilket som helst af kravene 1-10 og en farmaceutisk acceptabel bærer.
12. Isoleret cellelinje, der producerer det isolerede humane monoklonale antistof eller den antigenbindende del ifølge et hvilket som helst af kravene 1- 10.
13. Isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder for det isolerede humane monoklonale antistof eller den antigenbindende del ifølge et hvilket som helst af kravene 1-10.
14. Vektor omfattende nukleinsyremolekylet ifølge krav 13, hvor vektoren eventuelt omfatter en ekspressionskontrolsekvens, der er operativt forbundet med nukleinsyremolekylet.
15. Isoleret humant monoklonalt antistof eller antigenbindende del deraf ifølge et hvilket som helst af kravene 1-10 til terapeutisk anvendelse.
16. Anvendelse af det isolerede humane monoklonale antistof eller den antigenbindende del deraf ifølge et hvilket som helst af kravene 1-10 til fremstilling af et lægemiddel til behandling, forebyggelse eller lindring af symptomerne på en CCR2-medieret lidelse hos et individ med behov herfor, hvor den CCR2-medierede lidelse er udvalgt fra gruppen bestående af en inflammatorisk lidelse, en allergisk lidelse, en autoimmun lidelse, en transplantatsafstødningslidelse, aterosklerose, adipositas, HIV-infektion, neuropatiske smerter, stenose, restenose, multipel sklerose, en fibrotisk tilstand, aldersrelateret makuladegeneration, uveitis, hornhindeinfektion og cancer.
17. Isoleret humant monoklonalt antistof eller antigenbindende del deraf ifølge et hvilket som helst af kravene 1-10 eller farmaceutisk sammensætning ifølge krav 11 til anvendelse ved behandling, forebyggelse eller lindring af symptomerne på en CCR2-medieret lidelse, hvor den CCR2-medierede lidelse er udvalgt fra gruppen bestående af en inflammatorisk lidelse, en allergisk lidelse, en autoimmun lidelse, en transplantatsafstødningslidelse, aterosklerose, adipositas, HIV-infektion, neuropatiske smerter, stenose, restenose, multipel sklerose, en fibrotisk fibrotic tilstand, aldersrelateret makuladegeneration, uveitis, hornhindeinfektion og cancer.
18. Anvendelse ifølge krav 16 eller isoleret humant monoklonalt antistof eller antigenbindende del deraf til anvendelse ifølge krav 17 eller farmaceutisk sammensætning til anvendelse ifølge krav 17, hvor den fibrotiske tilstand er leverfibrose.
19. Anvendelse ifølge krav 18 eller isoleret humant monoklonalt antistof eller antigenbindende del deraf til anvendelse ifølge krav 18 eller farmaceutisk sammensætning til anvendelse ifølge krav 18, hvor leverfibrosen er resultatet af hepatitis C-virus (HCV)-infektion, hepatitis B-virus (HBV)-infektion, alkoholisk steatohepatitis (ASH) eller nonalkoholisk steatohepatitis (NASH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18935708P | 2008-08-18 | 2008-08-18 | |
PCT/US2009/004711 WO2010021697A2 (en) | 2008-08-18 | 2009-08-17 | Antibodies to ccr2 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2321351T3 true DK2321351T3 (da) | 2017-12-18 |
Family
ID=41347729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09789161.8T DK2321351T3 (da) | 2008-08-18 | 2009-08-17 | Antistoffer mod ccr2 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8710191B2 (da) |
EP (1) | EP2321351B1 (da) |
JP (1) | JP5685535B2 (da) |
KR (1) | KR101772706B1 (da) |
CN (1) | CN102239180B (da) |
AU (1) | AU2009283199B2 (da) |
BR (1) | BRPI0916973A2 (da) |
CA (1) | CA2734578C (da) |
CO (1) | CO6351802A2 (da) |
DK (1) | DK2321351T3 (da) |
ES (1) | ES2658117T3 (da) |
HK (1) | HK1163134A1 (da) |
IL (1) | IL211284A (da) |
MX (1) | MX2011001911A (da) |
MY (1) | MY160892A (da) |
NO (1) | NO2321351T3 (da) |
NZ (1) | NZ591471A (da) |
PE (1) | PE20110774A1 (da) |
RU (1) | RU2547595C2 (da) |
SG (2) | SG10201701323TA (da) |
WO (1) | WO2010021697A2 (da) |
ZA (1) | ZA201101047B (da) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011116299A2 (en) * | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
WO2011019679A1 (en) * | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Ccr2 inhibitors for treating conditions of the eye |
US8734790B2 (en) | 2011-01-10 | 2014-05-27 | Novimmune Sa | Anti-TLR4 antibodies and methods of use thereof |
CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
US20120288442A1 (en) * | 2011-05-11 | 2012-11-15 | Atomic Energy Council-Institute Of Nuclear Energy Research | Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis |
WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
WO2012172339A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory arthritis |
WO2012172336A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
WO2013041833A1 (en) | 2011-06-13 | 2013-03-28 | Ith Immune Therapy Holdings Ab | Treating conditions associated with metabolic syndrome |
DK2718311T3 (da) | 2011-06-13 | 2018-04-16 | Tla Targeted Immunotherapies Ab | Behandling af multipel sklerose |
US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
ES2637390T3 (es) | 2011-06-13 | 2017-10-13 | Tla Targeted Immunotherapies Ab | Tratamiento de afecciones respiratorias |
WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
EP2718312B1 (en) | 2011-06-13 | 2018-07-25 | TLA Targeted Immunotherapies AB | Treating conditions associated with sepsis |
WO2013089647A1 (en) * | 2011-12-16 | 2013-06-20 | Agency For Science, Technology And Research | Binding molecules against dengue virus and uses thereof |
CN105051065A (zh) * | 2012-06-22 | 2015-11-11 | 索伦托治疗有限公司 | 与ccr2结合的抗原结合蛋白 |
US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
WO2014165271A2 (en) * | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
EP3262418B1 (en) | 2015-02-26 | 2019-05-01 | Innovative Concepts in Drug Development | Diagnostic markers of cognitive impairments, kits and uses thereof |
MY197413A (en) | 2016-05-02 | 2023-06-16 | Prothena Biosciences Ltd | Antibodies recognizing tau |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
EP3463350B1 (en) | 2016-06-03 | 2023-09-13 | ChemoCentryx, Inc. | Pyrrolo-pyridines and pyrrolo-pyrimidines for use in treating liver fibrosis |
MX2021014356A (es) | 2016-11-23 | 2022-11-24 | Chemocentryx Inc | Metodo para tratar glomeruloesclerosis segmentaria focal. |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
AU2018347361A1 (en) | 2017-10-11 | 2020-04-30 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
CN111699003B (zh) * | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
BR112021000021A2 (pt) | 2018-07-03 | 2021-03-30 | Fennec Pharmaceuticals, Inc. | Tiossulfato de sódio anidro e formulações do mesmo |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
AU2019346645A1 (en) | 2018-09-27 | 2021-04-29 | Marengo Therapeutics, Inc. | CSF1R/CCR2 multispecific antibodies |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
JP2022515424A (ja) | 2018-12-24 | 2022-02-18 | サノフイ | 突然変異fabドメインを有する多重特異性結合タンパク質 |
EP3911954A4 (en) * | 2019-01-16 | 2022-11-02 | Yeda Research and Development Co. Ltd | BIOMARKERS FOR MODIFICATION OF CNS DISEASES |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
KR20220019670A (ko) * | 2019-04-17 | 2022-02-17 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제 |
US20220220212A1 (en) * | 2019-05-13 | 2022-07-14 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind ccr2 to modulate cellular function |
KR20220038356A (ko) * | 2019-06-26 | 2022-03-28 | 아뮤닉스 파마슈티컬스, 인크. | Egfr 항원 결합 단편 및 이를 포함하는 조성물 |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20220025436A1 (en) * | 2020-07-21 | 2022-01-27 | Rutgers, The State University Of New Jersey | Method and Kit For CCR2 Expression Profiling And Disease Stratification |
JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
IL311476A (en) | 2021-10-27 | 2024-05-01 | Granite Bio Ag | CCR2-directed antibodies |
CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
NZ246242A (en) * | 1991-12-02 | 1996-01-26 | Cor Therapeutics Inc | Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf) |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2218489A1 (en) | 1995-04-21 | 1996-10-24 | Aya Jakobovits | Generation of large genomic dna deletions |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 cd147 결합 분자 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
WO2001057226A1 (en) | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
US20030165988A1 (en) * | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
ATE517855T1 (de) | 2001-11-30 | 2011-08-15 | Biogen Idec Inc | Antikörper gegen chemotaktische monozytenproteine |
AU2003209059A1 (en) * | 2002-02-08 | 2003-09-02 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
UA87979C2 (ru) | 2002-08-19 | 2009-09-10 | Астразенека Аб | Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1) |
EP1538207B1 (en) | 2002-09-12 | 2010-06-02 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Human anti-human mcp-1 antibody and antibody fragment thereof |
JP2007521248A (ja) | 2003-12-10 | 2007-08-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヒト化抗ccr2抗体および該抗体を使用する方法 |
SG10201606980VA (en) | 2004-06-03 | 2016-10-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
EP1784425A4 (en) | 2004-06-30 | 2009-02-18 | Centocor Inc | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
EP1778285A2 (en) * | 2004-07-30 | 2007-05-02 | Pfizer Products Inc. | Treatment of ccr2 mediated diseases or disorders |
JP2010505878A (ja) | 2006-10-05 | 2010-02-25 | セントコア・オーソ・バイオテツク・インコーポレーテツド | 線維症の処置のためのccr2アンタゴニスト |
-
2009
- 2009-08-17 EP EP09789161.8A patent/EP2321351B1/en active Active
- 2009-08-17 NZ NZ591471A patent/NZ591471A/xx unknown
- 2009-08-17 WO PCT/US2009/004711 patent/WO2010021697A2/en active Application Filing
- 2009-08-17 BR BRPI0916973A patent/BRPI0916973A2/pt not_active IP Right Cessation
- 2009-08-17 ES ES09789161.8T patent/ES2658117T3/es active Active
- 2009-08-17 CN CN200980136307.1A patent/CN102239180B/zh not_active Expired - Fee Related
- 2009-08-17 US US13/059,702 patent/US8710191B2/en active Active
- 2009-08-17 MX MX2011001911A patent/MX2011001911A/es active IP Right Grant
- 2009-08-17 AU AU2009283199A patent/AU2009283199B2/en not_active Ceased
- 2009-08-17 KR KR1020117006355A patent/KR101772706B1/ko active IP Right Grant
- 2009-08-17 JP JP2011523807A patent/JP5685535B2/ja active Active
- 2009-08-17 NO NO09789161A patent/NO2321351T3/no unknown
- 2009-08-17 SG SG10201701323TA patent/SG10201701323TA/en unknown
- 2009-08-17 CA CA2734578A patent/CA2734578C/en active Active
- 2009-08-17 SG SG2013063318A patent/SG193216A1/en unknown
- 2009-08-17 DK DK09789161.8T patent/DK2321351T3/da active
- 2009-08-17 MY MYPI2011000512A patent/MY160892A/en unknown
- 2009-08-17 PE PE2011000160A patent/PE20110774A1/es active IP Right Grant
- 2009-08-17 RU RU2011110169/10A patent/RU2547595C2/ru active
-
2011
- 2011-02-09 ZA ZA2011/01047A patent/ZA201101047B/en unknown
- 2011-02-17 IL IL211284A patent/IL211284A/en active IP Right Grant
- 2011-03-11 CO CO11030038A patent/CO6351802A2/es active IP Right Grant
-
2012
- 2012-04-17 HK HK12103743.0A patent/HK1163134A1/xx not_active IP Right Cessation
-
2014
- 2014-04-03 US US14/244,167 patent/US9238691B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2321351T3 (da) | Antistoffer mod ccr2 | |
JP6189281B2 (ja) | ヒトc−fms抗原結合性タンパク質 | |
KR101859911B1 (ko) | 사람 gdf8에 대한 항체 | |
JP2016105704A (ja) | β‐クロトー、FGF受容体、およびその複合体と結合するヒト抗原結合タンパク質 | |
KR20110031152A (ko) | Il-6에 대한 항체 및 그의 용도 | |
JP2005530490A (ja) | インターロイキン−5に対するヒトモノクローナル抗体および方法およびこれを含む組成物 | |
CN111303285B (zh) | 靶向ox40的抗体及其制备方法和应用 | |
CN105218672A (zh) | 优先结合人csf1r胞外域4的抗体及其用途 | |
JP2022527373A (ja) | Retを結合するヒト抗体およびその使用方法 | |
KR20230009501A (ko) | 항-glp1r 길항제 항체 및 이의 이용 방법 | |
JP3979008B2 (ja) | G−csfレセプターアゴニスト抗体及びそのスクリーニング方法 | |
TW201223543A (en) | Anti-VEGFR-3 antibody compositions | |
GLADUE et al. | Patent 2734578 Summary | |
RU2821548C2 (ru) | Человеческие антитела, связывающие ret, и способы их применения |